UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of July, 2019
 
Commission File Number 001-15170
 
 
GlaxoSmithKline plc
(Translation of registrant's name into English)
 
 
 980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
 
 
 
GlaxoSmithKline plc (the ' Company ')
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Ms E Walmsley
 
b)
Position/status
Chief Executive Officer
 
c)
Initial notification/
amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
 
c)
Price(s) and
volume(s)
 
 
 
 
 
Price(s)
Volume(s)
 
 
£ 16.3240
209.000
 
 
£ 16.3240
730.000
 
 
£ 16.3240
733.000
 
 
£ 16.3240
209.000
 
 
 
 
 
d)
Aggregated information
 
Aggregated volume Price
1881.000
 
£ 16.3240
 
e)
Date of the transaction
2019-07-12  
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Mr R G Connor
 
b)
Position/status
President, Global Vaccines
 
c)
Initial notification/
amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
 
c)
Price(s) and
volume(s)
 
 
 
 
 
Price(s)
Volume(s)
 
 
£ 16.3240
191.000
 
 
£ 16.3240
109.000
 
 
£ 16.3240
155.000
 
 
£ 16.3240
109.000
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume Price
564.000
 
 
£ 16.3240
 
 
e)
Date of the transaction
2019-07-12
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Mr N Hirons
 
b)
Position/status
SVP, Global Ethics & Compliance
 
c)
Initial notification/
amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
 
c)
Price(s) and
volume(s)
 
 
 
 
 
Price(s)
Volume(s)
 
 
£ 16.3240
80.000
 
 
£ 16.3240
68.000
 
 
£ 16.3240
81.000
 
 
£ 16.3240
68.000
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume Price
297.000
 
 
£ 16.3240
 
 
e)
Date of the transaction
2019-07-12
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
 
a)
Name
Mr L Miels
 
 
b)
Position/status
President, Global Pharmaceuticals
 
 
c)
Initial notification/
amendment
 
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
 
a)
Name
GlaxoSmithKline plc
 
 
b)
LEI
5493000HZTVUYLO1D793
 
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
 
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
 
 
c)
Price(s) and
volume(s)
 
 
 
 
 
Price(s)
Volume(s)
 
 
£ 16.3240
203.000
 
 
£ 16.3240
147.000
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume Price
350.000
 
 
£ 16.3240
 
 
e)
Date of the transaction
2019-07-12
 
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
 
a)
Name
Mr D Redfern
 
 
b)
Position/status
Chief Strategy Officer
 
 
c)
Initial notification/
amendment
 
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
 
a)
Name
GlaxoSmithKline plc
 
 
b)
LEI
5493000HZTVUYLO1D793
 
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
 
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
 
 
c)
Price(s) and
volume(s)
 
 
 
 
 
Price(s)
Volume(s)
 
 
£ 16.3240
86.000
 
 
£ 16.3240
181.000
 
 
£ 16.3240
150.000
 
 
£ 16.3240
86.000
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume Price
503.000
 
£ 16.3240
 
e)
Date of the transaction
2019-07-12
 
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Mr R Simard
 
b)
Position/status
President, Pharmaceuticals Supply Chain
 
c)
Initial notification/
amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
 
c)
Price(s) and volume(s)
 
 
 
 
 
Price(s)
Volume(s)
 
 
£ 16.3240
65.000
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume Price
N/A
 
 
 
 
e)
Date of the transaction
2019-07-12
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Mr P C Thomson
 
b)
Position/status
President, Global Affairs
 
c)
Initial notification/
amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 
 
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
 
c)
Price(s) and
volume(s)
 
 
 
 
 
Price(s)
Volume(s)
 
 
£ 16.3240
105.000
 
 
£ 16.3240
82.000
 
 
£ 16.3240
102.000
 
 
 
 
 
d)
Aggregated information
 
Aggregated volume Price
289.000
 
£ 16.3240
 
e)
Date of the transaction
2019-07-12
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Mr B McNamara
 
b)
Position/status
CEO, GSK Consumer Healthcare
 
c)
Initial notification/
amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053 
 
 
b)
Nature of the transaction
Increase in notional interest in ADS following the re-investment of dividends paid to shareholders on 11 July 2019 on ADS held in the Company's Deferred Annual Bonus Plan.
 
c)
Price(s) and
volume(s)
 
 
 
 
 
Price(s)
Volume(s)
 
 
$ 40.9300
76.000
 
 
$ 40.9300
78.000
 
 
$ 40.9300
72.000
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume Price
226.000
 
 
$ 40.9300
 
e)
Date of the transaction
2019-07-12
 
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Dr H Barron
 
b)
Position/status
 Chief Scientific Officer and President, R&D
 
c)
Initial notification/
amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053 
 
 
b)
Nature of the transaction
Increase in notional interest in ADS following the re-investment of dividends paid to shareholders on 11 July 2019 on ADS held in the Company's Deferred Annual Bonus Plan.
 
c)
Price(s) and
volume(s)
 
 
 
 
 
Price(s)
Volume(s)
 
 
$ 40.9300
428.000
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume Price
n/a
 
 
 
 
 
e)
Date of the transaction
2019-07-12
 
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Mr J Ford
 
b)
Position/status
SVP and General Counsel
 
c)
Initial notification/
amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053 
 
 
b)
Nature of the transaction
Increase in notional interest in ADS following the re-investment of dividends paid to shareholders on 11 July 2019 on ADS held in the Company's Deferred Annual Bonus Plan.
 
c)
Price(s) and
volume(s)
 
 
 
 
 
Price(s)
Volume(s)
 
 
$ 40.9300
36.000
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume Price
n/a
 
e)
Date of the transaction
2019-07-12
 
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Ms K Terrell
 
b)
Position/status
Chief Digital & Technology Officer
 
c)
Initial notification/
amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GlaxoSmithKline plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053 
 
 
b)
Nature of the transaction
Increase in notional interest in ADS following the re-investment of dividends paid to shareholders on 11 July 2019 on ADS held in the Company's Deferred Annual Bonus Plan.
 
c)
Price(s) and
volume(s)
 
 
 
 
 
Price(s)
Volume(s)
 
 
$ 40.9300
25.000
 
 
$ 40.9300
91.000
 
 
 
 
 
d)
Aggregated information
 
 
Aggregated volume Price
116.000
 
 
$ 40.9300
 
e)
Date of the transaction
2019-07-12
 
f)
Place of the transaction
 
New York Stock Exchange (XNYS)
 
  
 
 
 
 
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GlaxoSmithKline plc
 
(Registrant)
 
 
Date: July 15, 2019 
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GlaxoSmithKline plc
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GSK (NYSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more GSK Charts.